Subject(s)
Diagnostic Errors , Eosinophilia/diagnosis , Fasciitis/diagnosis , POEMS Syndrome/diagnosis , Cyclosporine/therapeutic use , Hepatomegaly/etiology , Humans , Hyperpigmentation/etiology , Immunoglobulin G/blood , Immunoglobulin lambda-Chains/blood , Immunosuppressive Agents/therapeutic use , Male , Methotrexate/therapeutic use , Middle Aged , Paresthesia/etiology , Peripheral Nervous System Diseases/etiology , Prednisone/therapeutic use , Reflex, Abnormal , Skin/pathology , Vascular Endothelial Growth Factor A/bloodSubject(s)
Lupus Erythematosus, Cutaneous/immunology , Animals , Cytokines/metabolism , DNA/immunology , Disease Models, Animal , Gene Expression Profiling , Humans , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/etiology , Lupus Erythematosus, Cutaneous/genetics , Lupus Erythematosus, Cutaneous/metabolism , Lupus Erythematosus, Cutaneous/physiopathology , Lupus Erythematosus, Cutaneous/therapy , Mice , Photosensitivity Disorders/etiology , Photosensitivity Disorders/immunologyABSTRACT
OBJECTIVE: To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism. DESIGN: Prospective randomized clinical study. SETTING: University hospital. PATIENT(S): Forty-one women (median age, 21 years [range, 18-34 years]) with idiopathic hirsutism who had requested to use an oral contraceptive. INTERVENTION(S): Patients were randomly assigned to receive cyproterone acetate (12.5 mg/d for the first 10 days of the cycle), finasteride (5 mg/d), or spironolactone (100 mg/d) for 12 months. Follow-up was done at the end of therapy. MAIN OUTCOME MEASURE(S): Ferriman-Gallwey score before treatment, at 6 and 12 months of treatment, and 1 year after the end of treatment, and androgenic profile before and after treatment. RESULT(S): At the end of therapy, the Ferriman-Gallwey score decreased by 38.9%, 38.6%, and 38.5% in patients who used cyproterone acetate, finasteride, and spironolactone, respectively. One year after therapy, the Ferriman-Gallwey score of patients who used spironolactone was significantly lower (6.74 +/- 1.41) than that of patients who used either cyproterone acetate (7.92 +/- 1.08), or finasteride (9.08 +/- 0.99). The androgenic profile did not change significantly during treatment. CONCLUSION(S): In patients with idiopathic hirsutism, the short-term results of treatment with cyproterone acetate, finasteride, and spironolactone are similar, but spironolactone is effective for a longer time.
